MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Rocket Pharmaceuticals Inc

Abrir

SetorSaúde

7.34 -0.81

Visão Geral

Variação de preço das ações

24h

Atual

Mín

7.13

Máximo

7.49

Indicadores-chave

By Trading Economics

Rendimento

6.4M

-60M

EPS

-0.62

Funcionários

299

EBITDA

6.4M

-57M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+465.28% upside

Dividendos

By Dow Jones

Próximos Ganhos

2 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-304M

765M

Abertura anterior

8.15

Fecho anterior

7.34

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bullish Evidence

Rocket Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

28 de jun. de 2024, 14:25 UTC

Grandes Movimentos do Mercado

Rocket Pharmaceuticals Shares Slide After FDA Rejects Kresladi

Comparação entre Pares

Variação de preço

Rocket Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

465.28% parte superior

Previsão para 12 meses

Média 42 USD  465.28%

Máximo 55 USD

Mínimo 15 USD

Com base em 15 analistas de Wall Street que oferecem metas de preço de 12 meses para Rocket Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

15 ratings

14

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

5.9 / 7.44Suporte e Resistência

Curto Prazo

Very Strong Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

No Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.